| [1] |
Dawood S, Ueno NT, Valero V, et al. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early [J]. Cancer,2012,118(4):1171-1172.
|
| [2] |
Lee BJ,Tannenbaum NE.Inflammatory carcinoma of the breast:a report of twenty-eight cases from the breast clinic of the Memorial Hospital[J]. Surg Gynecol Obestet,1924,39:580-595.
|
| [3] |
Robertson FM, Bondy M, Yang W, et al. Inflammatory breast cancer: the disease,the biology, the treatment[J]. CA Cancer J Clin,2010,60(6):351-375.
|
| [4] |
Kumar N,Sayed S,Moloo Z, et al. Fine-needle aspiration in suspected inflammatory breast cancer:case series with emphasis on approach to specimen adequacy[J]. Acta Cytol,2011,55(3):239-244.
|
| [5] |
Dobbs J, Krishnamurthy S, Kyrish M, et al. Confocal fluorescence microscopy for rapid evaluation of invasive tumor cellularity of inflammatory breast carcinoma core needle biopsies[J]. Breast Cancer Res Treat,2015,149(1):303-310.
|
| [6] |
Goldner B,Behrendt CE,Schoellhammer HF,et al.Incidence of inflammatory breast cancer in women, 1992 -2009, United States[J].Ann Surg Oncol,2014,21(4):1267-1270.
|
| [7] |
Woodward WA, Debeb BG, Xu W, et al. Overcoming radiation resistance in inflammatory breast cancer[J]. Cancer,2010,116(11):2840-2845.
|
| [8] |
Bozzetti F, Saccozzi R, De Lena M,et al. Inflammatory cancer of the breast:analysis of 114 cases[J]. J Surg Oncol, 1981,18(4):355-361.
|
| [9] |
Dawood S, Ueno NT, Valero V, et al. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large populationbased study[J]. Cancer,2011,117(9):1819-1826.
|
| [10] |
Sinclair S, Sandra SM. Primary systemic chemotherapy for inflammatory breast cancer [J]. Cancer,2010,116 (11):2821-2828.
|
| [11] |
Hoffman HJ, Khan A, Ajmera KM, et al. Initial response to chemotherapy, not delay in diagnosis, predicts overall survival in inflammatory breast cancercases[J].Am J Clin Oncol,2014,37(4):315-321.
|
| [12] |
Viens P, Tarpin C, Roche H, et al. Systemic therapy of inflammatory breast cancer from high-dose chemotherapy totargeted therapies[J].Cancer,2010,116(11):2829-2836.
|
| [13] |
Horváth Z, Torday L, Hitre E, et al. Inflammatory breast cancer-comparing the effectivity of preoperative docetaxelepirubicine protocol to conventional antracycline-containing chemotherapy to achieve clinical benefit and complete pathological response[J]. Pathol Oncol Res,2011,17(3):541-550.
|
| [14] |
Ardavanis A,Scorilas A,Tryfonopoul D,et al.Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine,and fluorouracil chemotherapy, surgery, and radiotherapy:long-term results[J]. Oncologist,2006,11(6):563-573.
|
| [15] |
Dawood S, Merajver SD, Viens P, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment[J]. Ann Oncol,2011,22(3):515-523.
|
| [16] |
Bonev V, Evangelista M, Chen JH, et al.Long-term follow-up of breast conserving therapy in inflammatory breast cancer patients treated with neojuvant chemotherapy[J]. Am Surg,2014,80(10):940-943.
|
| [17] |
Abrous-Anane A, Savignoni A,Daveau C,et al.Management of inflammatory breast cancer after neo-adjuvant chemotherapy[J].Cancer Radiother,2011,15(8):654-662.
|
| [18] |
Fleming RY, Asmar L, Buzdar AU, et al. Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma[J]. Ann Surg Oncol, 1997,4(6):452-461.
|
| [19] |
Akay CL, Ueno NT, Chisholm GB, et al. Primary tumor resection as a component of multimodality treatment may improve local control and survival in stage IV inflammatory breast cancer[J].Cancer,2014,120(9):1319-1328.
|
| [20] |
Scotti V, Desideri I, Meattini I, et al. Management of inflammatory breast cancer: focus on radiotherapy with an evidence-based approach[J].Cancer Treat Rev,2013,39(2):119-124.
|
| [21] |
Bourgier C, Pessoa EL, Dunant A,et al. Exclusive alternating chemotherapy and radiotherapy in nonmetastatic inflammatory breast cancer:20 years of follow-up[J].Int J Radiat Oncol Biol Phys,2012,82(2):690-695.
|
| [22] |
Turpin E, Bieche I, Berthaeau P, et al. The increased incidence of ERBB2 over expression and TP53 mutation in inflammatory breast cancer[J]. Oncogene,2002,21(49):7593-7597.
|
| [23] |
von Minckwitz G, Rezai M, Loibl S, et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase II GeparQuattro study [J]. J Clin Oncol, 2010, 28 (12):2015-2023.
|
| [24] |
Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versusneoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort[J].Lancet,2010,375(9712):377-384.
|
| [25] |
Kaufman B, Mackey JR, Clemens MR, et al.Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study[J].J Clin Oncol,2009,27(33):5529-5537.
|
| [26] |
Gelmon KA, Boyle FM, Kaufman B, et al. Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: final results of NCIC CTG MA.31 [J]. J Clin Oncol,2015,33 (14):1574-1583.
|
| [27] |
Vermeulen PB, van Golen KL, Dirix LY. Angiogenesis,lymphangiogenesis, growth pattern, and tumor emboli in inflammatory breast cancer: a review of the current knowledge[J]. Cancer,2010,116(11):2748-2754.
|
| [28] |
Pierga JY,Petit T,Delozier T,et al.Neoadjuvant bevacizumab,trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer(BEVERLY-2): an open-label,single-arm phase 2 study[J].Lancet Oncol,2012,13(4):375-384.
|
| [29] |
Cuzick J, Sestak I, Baum M,et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer:10-year analysis of the ATAC trial[J]. Lancet Oncol,2010,11(12):1135-1141.
|
| [30] |
Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer[J]. N Engl J Med,2005,353(26):2747-2757.
|
| [31] |
Gonzalez-Angulo AM, Hennessy BT, Broglio K,et al. Trends for inflammatory breast cancer: is survival improving? [J].Oncologist,2007,12(8):904-912.
|
| [32] |
Dawood S, Lei X, Dent R,et al. Survival of women with inflammatory breast cancer:a large population-based study[J].Ann Oncol,2014,25(6):1143-1151.
|
| [33] |
Ahmed S,Lawrence J,Stewart JH,et al. Does age predict outcome in patients with inflammatory breast cancer? [J]. Am Surg,2014,80(8):E221-224.
|
| [34] |
Kolarevic D, Tomasevic Z, Dzodic R, et al. Clinical and pathological response to induction chemotherapy used as a prognostic factor in inflammatory breast cancer[J]. J BUON,2012,17(1):21-26.
|